Optimizing treatment strategies for early‐onset mucinous adenocarcinoma of the colon: A SEER database analysis
Colorectal Disease · 2026-02 · 28 (2)
DOI: 10.1111/codi.70390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Colorectal Disease, online erschienen am 14.02.2026. Verfasst von Cameron Perrone und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida, USA. Hauptthemen laut MEDLINE: Adenocarcinoma, Mucinous, Colectomy, Colonic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Background
Colorectal mucinous adenocarcinoma (MAC) is challenging due to its unique pathophysiology and increasing incidence in younger populations. Treatment guidelines for early‐onset MAC remain unclear, with clinical decisions often based on extrapolated data from classical adenocarcinoma. We aimed to assess the association between the extent of surgical resection and systemic therapy in patients with early‐onset colonic MAC and survival.
Methods
Retrospective cohort analysis of patients aged 20–50 with stage II–III colonic MAC using the SEER database (2000–2020). We evaluated overall survival (OS) and cancer‐specific survival (CSS) based on surgical resection (segmental vs. extended) and systemic therapy, using Kaplan–Meier and Cox regression analyses.
Results
The cohort included 2553 patients (58.5% male; mean age 42.7 years). Segmental resection was performed in 27.6%. Extended resection was more commonly performed in right‐sided and stage III disease. Systemic therapy was administered to 62.1%, predominantly for stage III disease with unfavourable tumour features. Systemic therapy was associated with improved restricted mean 5‐year CSS (51.7 vs. 47.8 months, p = 0.041) and OS (51.1 vs. 45.9 months, p = 0.008) in stage III, but not stage II, disease. Extended resection was associated with a modest survival benefit for CSS (56.5 vs. 54.3 months, p = 0.027) and OS (56.0 vs. 53.3 months, p = 0.007) in stage II, but not stage III, disease.
Conclusion
Systemic therapy was associated with a significant survival benefit in patients with stage III early‐onset MAC, supporting its role as a cornerstone of treatment despite the histology's presumed chemoresistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, Florida, USA.
- Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida, USA.
- Colorectal Surgery Unit, General Surgery Department, Mansoura University Hospitals, Mansoura, Egypt.
- Department of Colorectal Surgery, Medstar Georgetown University Health, Washington, DC, USA.
ORCID-Profile: Steven D Wexner
Zitieren
APA
Perrone, C., Emile, S. H., Lopez, C., Barnes, S., Wignakumar, A., Bilotti, M., & Wexner, S. D. (2026). Optimizing treatment strategies for early‐onset mucinous adenocarcinoma of the colon: A SEER database analysis. Colorectal Disease, 28(2). https://doi.org/10.1111/codi.70390
Vancouver
Perrone C, Emile SH, Lopez C, Barnes S, Wignakumar A, Bilotti M, et al. Optimizing treatment strategies for early‐onset mucinous adenocarcinoma of the colon: A SEER database analysis. Colorectal Disease. 2026;28(2). doi:10.1111/codi.70390
BibTeX
@article{Perrone2026,
author = {Perrone, Cameron and Emile, Sameh Hany and Lopez, Christopher and Barnes, Spencer and Wignakumar, Anjelli and Bilotti, Matthew and Wexner, Steven D},
title = {Optimizing treatment strategies for early‐onset mucinous adenocarcinoma of the colon: A SEER database analysis},
journal = {Colorectal Disease},
year = {2026},
volume = {28},
number = {2},
doi = {10.1111/codi.70390}
}
EUVIMED